• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»autism spectrum disorder

Does MapLight Therapeutics, Inc. have the clinical design to compete in crowded neuropsychiatric markets?

By Soujanya Ravi on May 1, 2026   Pharma & Biotech  

Does MapLight Therapeutics, Inc. have the clinical design to compete in crowded neuropsychiatric markets?

MapLight Therapeutics nears key Phase 2 data in schizophrenia and autism. Discover how its trial design could shape CNS market competition.

Can EarliPoint Health and Netsmart reduce autism diagnosis bottlenecks in provider settings?

By Pallavi Madhiraju on April 4, 2026   Medical Devices & Diagnostics  

Can EarliPoint Health and Netsmart reduce autism diagnosis bottlenecks in provider settings?

EarliPoint Health and Netsmart are expanding access to autism assessment technology. Read what this could change for providers, workflows, and adoption.

Recent Posts

  • Could DermaSensor’s NHS study turn AI skin cancer tools into primary care infrastructure?
  • GlycoNex targets Prolia and Xgeva space as SPD8 meets Phase III equivalence goal
  • Could KARL STORZ’s Rubina Lens turn open surgery into the next imaging battleground?
  • Elixiron’s oral Alzheimer’s drug data raise a bigger question: can neuroinflammation become the next serious treatment target?
  • Apnimed advances oral OSA therapy case as AD109 heads toward FDA decision window
  • Optimi Health’s first UK psilocybin export signals bigger test for GMP psychedelic manufacturing
  • Why Cartesian Therapeutics’ WestGene pact could intensify the race for autoimmune cell therapy
  • Why FDA alignment could move Alterity’s ATH434 closer to a pivotal MSA test
  • Why TG Therapeutics’ BRIUMVI data could open a new treatment path in myasthenia gravis
  • Harbour BioMed’s HBM7004 China IND acceptance sharpens the race for B7-H4 cancer targets
  • Sensorion’s SENS-601 strategy signals a sharper bet on larger genetic hearing loss markets
  • Can Zetagen’s ZetaMet Phase 2a data change how metastatic breast cancer bone lesions are treated?
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes